Presented by Jessica Palmer at the American Society for Cellular and Computational Toxicology; October, 2020
Previous work showed that the potency ranking from devTOXqP assay was consistent with in vivo developmental toxicity potency, but whether the assay could quantitatively predict in vivo exposure exerting developmental toxicity was unknown.
Presented by Jessica Palmer, MSAssociate Director, ToxicologyStemina Biomarker Discovery, Inc. View the PowerPoint Presentation Watch the YouTube Video
Presented by Jessica Palmer, MSAssociate Director, ToxicologyStemina Biomarker Discovery, Inc. View the PowerPoint Presentation Watch the Webinar on YouTube
Presented by Jessica Palmer at the Safety Pharmacology Society Meeting in Barcelona, Spain; September, 2019
Tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis for a wide range of cancers. Unfortunately, numerous TKIs produce cardiotoxic effects, which were not well predicted during preclinical studies.
Presented at the Society of Toxicology Annual Meeting and ToxExpo in Baltimore, Maryland; March 2019.
Tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis for a wide range of cancers but often cause cardiotoxic effects. We developed an in vitro assay, Cardio quickPredict, for predicting cardiovascular liability based on changes in human iPSC-derived cardiomyocytes (iPSC-CM) metabolism and cell viability, which identifies both functional and structural cardiotoxicants.
President, CEO and Director – Biotheranostics, Inc
Stemina’s neurological disorders business unit has developed a test to aid in the earlier diagnosis of autism spectrum disorder.